Novo Nordisk A/S NVO

NVO Company Overview

Novo Nordisk A/S is a Denmark-based global healthcare company focused primarily on diabetes care, obesity treatments, and therapies for rare endocrine and blood disorders. The company operates within the pharmaceutical and biotechnology industries and is widely recognized for its leadership in insulin products and glucagon-like peptide-1 (GLP-1) therapies. Its major revenue drivers include diabetes medications such as Ozempic and Rybelsus, obesity treatments including Wegovy, and biopharmaceutical products for hemophilia and growth disorders. The company serves healthcare providers, hospitals, governments, insurers, and patients across both developed and emerging markets.

Founded in 1923 following the commercialization of insulin in Denmark, Novo Nordisk evolved through the merger of Novo Industri and Nordisk Gentofte in 1989. The company has since expanded from insulin manufacturing into broader chronic disease treatment areas, particularly obesity and metabolic disease management. Novo Nordisk’s strategic positioning is supported by its vertically integrated manufacturing capabilities, extensive biologics expertise, strong intellectual property portfolio, and significant scale in peptide-based therapeutics.